Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Incyte Corp (INCY)
Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,951,924
  • Shares Outstanding, K 223,088
  • Annual Sales, $ 3,395 M
  • Annual Income, $ 340,660 K
  • 60-Month Beta 0.72
  • Price/Sales 4.04
  • Price/Cash Flow 25.28
  • Price/Book 3.08
Trade INCY with:

Options Overview Details

View History
  • Implied Volatility 23.62% ( -7.54%)
  • Historical Volatility 29.28%
  • IV Percentile 11%
  • IV Rank 27.24%
  • IV High 41.97% on 06/30/22
  • IV Low 16.74% on 05/18/23
  • Put/Call Vol Ratio 0.03
  • Today's Volume 113
  • Volume Avg (30-Day) 540
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 14,649
  • Open Int (30-Day) 13,187

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 0.73
  • Number of Estimates 8
  • High Estimate 1.04
  • Low Estimate 0.43
  • Prior Year 0.85
  • Growth Rate Est. (year over year) -14.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.71 +3.01%
on 06/01/23
69.82 -10.43%
on 05/03/23
-7.42 (-10.61%)
since 05/02/23
3-Month
60.71 +3.01%
on 06/01/23
77.74 -19.55%
on 03/03/23
-14.77 (-19.10%)
since 03/02/23
52-Week
60.71 +3.01%
on 06/01/23
86.29 -27.52%
on 01/26/23
-12.09 (-16.20%)
since 06/02/22

Most Recent Stories

More News
3 Biotech Stocks Poised to Skyrocket

On the backs of successful trials and breakthrough therapies, the biotech market is poised to thrive. Therefore, scooping up the shares of fundamentally sound biotech stocks such as BioMarin Pharmaceutical...

BMRN : 93.36 (+5.78%)
INCY : 62.54 (+1.67%)
INVA : 13.17 (+0.46%)
MOR : 6.58 (+3.46%)
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D. President and Head of Research & Development (R&D) effective June 5, 2023. In this role and...

INCY : 62.54 (+1.67%)
Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y

Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.

NVS : 98.91 (+1.85%)
LLY : 442.33 (+1.34%)
INCY : 62.54 (+1.67%)
LGND : 75.31 (+5.77%)
Incyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to...

INCY : 62.54 (+1.67%)
Incyte (INCY) Q1 Earnings and Revenues Miss Estimates

Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

INCY : 62.54 (+1.67%)
XENE : 38.96 (+0.80%)
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

MMED.NE : 4.630 (-2.73%)
MNMD : 3.45 (-2.68%)
INCY : 62.54 (+1.67%)
SGEN : 195.38 (+0.36%)
PFE : 38.36 (+0.89%)
FBRX : 1.0250 (+0.49%)
JAZZ : 128.34 (-0.60%)
ALC : 79.46 (+1.07%)
Incyte: Q1 Earnings Snapshot

Incyte: Q1 Earnings Snapshot

INCY : 62.54 (+1.67%)
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (Nasdaq:INCY) today reports 2023 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.

INCY : 62.54 (+1.67%)
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura ® (ruxolitinib) cream 1.5% to control pruritus (itching) and reduce...

INCY : 62.54 (+1.67%)
The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte

Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte are included in this Analyst Blog.

GE : 105.80 (+1.08%)
NEE : 73.85 (+1.22%)
FMX : 102.50 (+1.17%)
INCY : 62.54 (+1.67%)
CHTR : 329.32 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 64.13
2nd Resistance Point 63.37
1st Resistance Point 62.95
Last Price 62.54
1st Support Level 61.77
2nd Support Level 61.01
3rd Support Level 60.59

See More

52-Week High 86.29
Fibonacci 61.8% 76.52
Fibonacci 50% 73.50
Fibonacci 38.2% 70.48
Last Price 62.54
52-Week Low 60.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar